TW201613902A - Difluoropyrrolidines as orexin receptor modulators - Google Patents
Difluoropyrrolidines as orexin receptor modulatorsInfo
- Publication number
- TW201613902A TW201613902A TW104126419A TW104126419A TW201613902A TW 201613902 A TW201613902 A TW 201613902A TW 104126419 A TW104126419 A TW 104126419A TW 104126419 A TW104126419 A TW 104126419A TW 201613902 A TW201613902 A TW 201613902A
- Authority
- TW
- Taiwan
- Prior art keywords
- disorder
- difluoropyrrolidines
- receptor modulators
- orexin receptor
- methods
- Prior art date
Links
- VWIGHVNBZXTEFC-UHFFFAOYSA-N 1,2-difluoropyrrolidine Chemical class FC1CCCN1F VWIGHVNBZXTEFC-UHFFFAOYSA-N 0.000 title abstract 2
- 108050000742 Orexin Receptor Proteins 0.000 title 1
- 102000008834 Orexin receptor Human genes 0.000 title 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000012672 seasonal affective disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037024P | 2014-08-13 | 2014-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201613902A true TW201613902A (en) | 2016-04-16 |
Family
ID=55304607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104126419A TW201613902A (en) | 2014-08-13 | 2015-08-13 | Difluoropyrrolidines as orexin receptor modulators |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10221170B2 (enExample) |
| EP (1) | EP3180332B1 (enExample) |
| JP (1) | JP6663909B2 (enExample) |
| AR (1) | AR101558A1 (enExample) |
| ES (1) | ES2901418T3 (enExample) |
| TW (1) | TW201613902A (enExample) |
| UY (1) | UY36272A (enExample) |
| WO (1) | WO2016025669A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| AU2017217931B2 (en) | 2016-02-12 | 2020-10-22 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| MD3426251T2 (ro) | 2016-03-10 | 2022-09-30 | Janssen Pharmaceutica Nv | Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2 |
| CN106278918B (zh) * | 2016-08-12 | 2018-05-11 | 合肥久诺医药科技有限公司 | 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法 |
| WO2018164191A1 (ja) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11034700B2 (en) | 2017-03-08 | 2021-06-15 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| CN111132975B (zh) * | 2017-09-28 | 2023-05-23 | 勃林格殷格翰国际有限公司 | N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺 |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7413261B2 (ja) | 2018-06-29 | 2024-01-15 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| TWI841671B (zh) | 2019-01-24 | 2024-05-11 | 日商第一三共股份有限公司 | 具有取代基之脲化合物 |
| SG11202106791XA (en) * | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| US11401814B2 (en) | 2020-01-17 | 2022-08-02 | Raytheon Technologies Corporation | Rotor assembly with internal vanes |
| US11286781B2 (en) | 2020-01-17 | 2022-03-29 | Raytheon Technologies Corporation | Multi-disk bladed rotor assembly for rotational equipment |
| US11434771B2 (en) | 2020-01-17 | 2022-09-06 | Raytheon Technologies Corporation | Rotor blade pair for rotational equipment |
| US11371351B2 (en) | 2020-01-17 | 2022-06-28 | Raytheon Technologies Corporation | Multi-disk bladed rotor assembly for rotational equipment |
| US11339673B2 (en) | 2020-01-17 | 2022-05-24 | Raytheon Technologies Corporation | Rotor assembly with internal vanes |
| US11208892B2 (en) | 2020-01-17 | 2021-12-28 | Raytheon Technologies Corporation | Rotor assembly with multiple rotor disks |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
Family Cites Families (158)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US5049578A (en) | 1990-03-09 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| DE69839355T2 (de) | 1997-07-29 | 2009-06-04 | Alcon Laboratories, Inc., Fort Worth | Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US6372757B1 (en) | 1998-05-08 | 2002-04-16 | Smithkline Beecham P.L.C. | Phenylurea and phenylthio urea derivatives |
| EP1150977B1 (en) | 1999-02-12 | 2004-08-25 | SmithKline Beecham plc | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| EP1144409B1 (en) | 1999-02-12 | 2004-11-17 | SmithKline Beecham plc | Phenyl urea and phenyl thiourea derivatives |
| CA2374947A1 (en) | 1999-05-24 | 2000-11-30 | Robert M. Scarborough | Inhibitors of factor xa |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| EP1288202A4 (en) | 2000-05-11 | 2003-07-02 | Banyu Pharma Co Ltd | N-acyltetrahydroisoquinoline derivatives |
| ES2238458T3 (es) | 2000-06-16 | 2005-09-01 | Smithkline Beecham Plc | Piperidinas para uso como antagonistas de los receptores de orexina. |
| WO2002044172A1 (en) | 2000-11-28 | 2002-06-06 | Smithkline Beecham P.L.C. | Morpholine derivatives as antagonists of orexin receptors |
| WO2002051232A2 (en) | 2000-12-27 | 2002-07-04 | Actelion Pharmaceuticals Ltd. | Novel benzazepines and related heterocyclic derivatives |
| WO2002090355A1 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
| WO2002089800A2 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
| GB0126292D0 (en) | 2001-11-01 | 2002-01-02 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| GB0130335D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130341D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| GB0130393D0 (en) | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| CA2460051A1 (en) | 2002-07-09 | 2004-01-15 | Actelion Pharmaceuticals Ltd. | 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| DE60309481T2 (de) | 2002-09-18 | 2007-06-21 | Glaxo Group Ltd., Greenford | Cyclische n-aroylamine als orexinrezeptorantagonisten |
| RU2334735C2 (ru) | 2002-10-11 | 2008-09-27 | Актелион Фармасьютиклз Лтд. | Производные сульфониламиноуксусной кислоты и их применение в качестве антагонистов рецепторов орексина |
| GB0225884D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225944D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225938D0 (en) | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| AU2003299648A1 (en) | 2002-12-12 | 2004-06-30 | Janssen Pharmaceutica, N.V. | Substituted 4-phenyl-(1,3)-dioxanes |
| ES2327737T3 (es) | 2003-03-26 | 2009-11-03 | Actelion Pharmaceuticals Ltd. | Derivados de tetrahidroisoquinolil acetamida para uso como antagonistas de receptores de orexina. |
| ES2297413T3 (es) | 2003-04-28 | 2008-05-01 | Actelion Pharmaceuticals Ltd. | Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina. |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| EP1654002B2 (en) | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| HUP0304101A3 (en) | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| HUP0400405A3 (en) | 2004-02-10 | 2009-03-30 | Sanofi Synthelabo | Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
| CA2557163C (en) | 2004-03-01 | 2011-08-16 | Idorsia Pharmaceuticals Ltd | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| WO2006067224A2 (en) | 2004-12-23 | 2006-06-29 | Biovitrum Ab (Publ) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists |
| WO2006110626A1 (en) | 2005-04-12 | 2006-10-19 | Merck & Co., Inc. | Amidopropoxyphenyl orexin receptor antagonists |
| WO2007008276A2 (en) | 2005-05-03 | 2007-01-18 | Ensemble Discovery Corporation | Turnover probes and use thereof for nucleic acid detection |
| WO2006127550A1 (en) | 2005-05-23 | 2006-11-30 | Merck & Co., Inc. | Proline bis-amide orexin receptor antagonists |
| US20090258903A1 (en) | 2005-08-04 | 2009-10-15 | Coleman Paul J | Aminoethane Sulfonamide Orexin Receptor Antagonists |
| JP2009506061A (ja) | 2005-08-26 | 2009-02-12 | メルク エンド カムパニー インコーポレーテッド | ジアザスピロデカンオレキシン受容体拮抗薬 |
| WO2007061763A2 (en) | 2005-11-22 | 2007-05-31 | Merck & Co., Inc. | Indole orexin receptor antagonists |
| CN101009515A (zh) | 2006-01-24 | 2007-08-01 | 华为技术有限公司 | 通信终端设备管理方法及通信终端 |
| TW200800020A (en) | 2006-01-26 | 2008-01-01 | Basf Ag | Methods to use 3-pyridyl derivatives as pesticides |
| FR2896798A1 (fr) | 2006-01-27 | 2007-08-03 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| FR2896799B1 (fr) | 2006-02-02 | 2008-03-28 | Sanofi Aventis Sa | Derives de sulfonamides, leur preparation et leur application en therapeutique |
| WO2007126934A2 (en) | 2006-03-29 | 2007-11-08 | Merck & Co., Inc. | Amidoethylthioether orexin receptor antagonists |
| EP2007717A1 (en) | 2006-04-11 | 2008-12-31 | Actelion Pharmaceuticals Ltd. | Novel sulfonamide compounds |
| DE602007012072D1 (de) | 2006-04-26 | 2011-03-03 | Actelion Pharmaceuticals Ltd | Orantagonisten |
| WO2007143813A1 (en) | 2006-06-16 | 2007-12-21 | Husky Injection Molding Systems Ltd. | Preventative maintenance update system |
| EP2049110B1 (en) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| US20090192143A1 (en) | 2006-07-14 | 2009-07-30 | Cox Christopher D | Substituted diazepan orexin receptor antagonists |
| AU2007272795A1 (en) | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | 2-substituted proline bis-amide orexin receptor antagonists |
| JP2010500401A (ja) | 2006-08-15 | 2010-01-07 | アクテリオン ファーマシューティカルズ リミテッド | アゼチジン化合物 |
| ATE458740T1 (de) | 2006-08-28 | 2010-03-15 | Actelion Pharmaceuticals Ltd | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten |
| JP2010504957A (ja) | 2006-09-29 | 2010-02-18 | アクテリオン ファーマシューティカルズ リミテッド | ３−アザ−ビシクロ［３．１．０］ヘキサン誘導体 |
| ES2357992T3 (es) | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| WO2008078291A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| TW200833328A (en) | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
| WO2008087611A2 (en) | 2007-01-19 | 2008-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidine- and piperidine- bis-amide derivatives |
| JP2010520206A (ja) | 2007-03-02 | 2010-06-10 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピリジンカルボキサミドオレキシン受容体アンタゴニスト |
| WO2008107335A1 (en) | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
| CN101636378A (zh) | 2007-03-15 | 2010-01-27 | 弗·哈夫曼-拉罗切有限公司 | 作为食欲肽拮抗剂的丙二酰胺类 |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| MX2009010727A (es) | 2007-04-04 | 2009-10-26 | Hoffmann La Roche | Heterociclos como antagonistas de orexina. |
| US20100222328A1 (en) | 2007-05-14 | 2010-09-02 | Hamed Aissaoui | 2-cyclopropyl-thiazole derivatives |
| JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| AU2008260647A1 (en) | 2007-05-23 | 2008-12-11 | Merck Sharp & Dohme Corp. | Cyclopropyl pyrrolidine orexin receptor antagonists |
| NZ580887A (en) | 2007-05-23 | 2012-03-30 | Merck Sharp & Dohme | Pyridyl piperidine orexin receptor antagonists |
| ES2371514T3 (es) | 2007-07-03 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | Compuestos de 3-aza-biciclo[3.3.0]octano. |
| EP2183246A2 (en) | 2007-07-27 | 2010-05-12 | Actelion Pharmaceuticals Ltd. | 2-aza-bicyclo-[3.3.0]-octane derivatives |
| EP2185512B1 (en) | 2007-07-27 | 2010-12-29 | Actelion Pharmaceuticals Ltd. | Trans-3-aza-bicyclo[3.1.0]hexane derivatives |
| EP2185503A1 (en) | 2007-08-02 | 2010-05-19 | F. Hoffmann-Roche AG | Monoamide derivatives as orexin receptor antagonists |
| CA2695621A1 (en) | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| US8263591B2 (en) | 2007-08-10 | 2012-09-11 | Cortex Pharmaceuticals, Inc. | Bicyclic amides for enhancing glutamatergic synaptic responses |
| KR20100055464A (ko) | 2007-08-15 | 2010-05-26 | 액테리온 파마슈티칼 리미티드 | 오렉신 길항제로서의 1,2-디아미도-에틸렌 유도체 |
| JP2010540429A (ja) | 2007-09-24 | 2010-12-24 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類 |
| AU2008319419A1 (en) | 2007-10-29 | 2009-05-07 | Merck Sharp & Dohme Corp. | Substituted diazepan orexin receptor antagonists |
| EP2231155A4 (en) | 2007-12-18 | 2011-09-14 | Concert Pharmaceuticals Inc | Tetrahydroisoquinoline DERIVATIVES |
| AU2008340421B2 (en) | 2007-12-21 | 2013-12-19 | F. Hoffmann-La Roche Ag | Heteroaryl derivatives as orexin receptor antagonists |
| BRPI0906522A2 (pt) | 2008-01-21 | 2015-07-14 | Hoffmann La Roche | Sulfonamidas como antagonistas de orexina |
| JP5346043B2 (ja) | 2008-02-12 | 2013-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | ピペリジンスルホンアミド誘導体 |
| ES2385699T3 (es) | 2008-02-21 | 2012-07-30 | Actelion Pharmaceuticals Ltd. | Derivados de 2-aza-biciclo-[2,2,1]heptano |
| GB0806536D0 (en) | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| CA2726102A1 (en) | 2008-06-11 | 2009-12-17 | Actelion Pharmaceuticals Ltd | Tetrazole compounds as orexin receptor antagonists |
| JP2011524398A (ja) | 2008-06-16 | 2011-09-01 | エフ．ホフマン−ラ ロシュ アーゲー | オレキシニン受容体アンタゴニストとしてのヘテロ芳香族モノアミド |
| CN102076694A (zh) | 2008-06-25 | 2011-05-25 | 埃科特莱茵药品有限公司 | 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物 |
| WO2010004507A1 (en) | 2008-07-07 | 2010-01-14 | Actelion Pharmaceuticals Ltd | Thiazolidine compounds as orexin receptor antagonists |
| WO2010012620A1 (en) | 2008-07-29 | 2010-02-04 | F. Hoffmann-La Roche Ag | Pyrrolidin-3-ylmethyl-amine as orexin antagonists |
| AR072899A1 (es) | 2008-08-07 | 2010-09-29 | Merck Sharp & Dohme | Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad. |
| EP2161266A1 (en) | 2008-08-22 | 2010-03-10 | EVOTEC Neurosciences GmbH | Benzofuran derivatives as orexin receptor antagonists |
| WO2010038200A1 (en) | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| CA2739344A1 (en) | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| EP2349270B1 (en) | 2008-10-21 | 2015-09-09 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| JP2012506374A (ja) | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト |
| WO2010048014A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,4-disubstituted pyrrolidine orexin receptor antagonists |
| EP2348846B1 (en) | 2008-10-21 | 2013-08-28 | Merck Sharp & Dohme Corp. | Disubstituted azepan orexin receptor antagonists |
| WO2010048016A1 (en) | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| US8710076B2 (en) | 2008-10-21 | 2014-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| MX2011004551A (es) | 2008-10-30 | 2011-05-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida. |
| AU2009308982A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| US8399494B2 (en) | 2008-10-30 | 2013-03-19 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| EP2358713A1 (en) | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Imidazopyridazine derivatives acting as orexin antagonists |
| WO2010060471A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| WO2010060470A1 (en) | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Piperidine derivatives useful as orexin receptor antagonists |
| US20100144760A1 (en) | 2008-12-02 | 2010-06-10 | Giuseppe Alvaro | Novel compounds |
| AU2009324238A1 (en) | 2008-12-02 | 2010-06-10 | Glaxo Group Limited | N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof |
| JP2010155827A (ja) | 2008-12-04 | 2010-07-15 | Takeda Chem Ind Ltd | スピロ環化合物 |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| WO2010086366A1 (en) | 2009-01-30 | 2010-08-05 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| EP2421850A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | 3 -azabicyclo [4.1.0]heptanes used as orexin antagonists |
| WO2011005636A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Tetrahydronapthyridine orexin receptor antagonists |
| EP2275421A1 (en) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| WO2011016234A1 (en) | 2009-08-04 | 2011-02-10 | Raqualia Pharma Inc. | Picolinamide derivatives as ttx-s blockers |
| WO2011023585A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| JP2013502447A (ja) | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体 |
| JP5847087B2 (ja) | 2009-10-23 | 2016-01-20 | ヤンセン ファーマシューティカ エヌ．ベー． | オレキシン受容体調節因子としての縮合複素環式化合物 |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| WO2011050202A1 (en) | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| WO2011053522A1 (en) | 2009-10-29 | 2011-05-05 | Merck Sharp & Dohme Corp. | Tertiary amide orexin receptor antagonists |
| US20120258957A1 (en) | 2009-11-23 | 2012-10-11 | Matilda Jane Bingham | Heterocyclic derivatives |
| WO2011073316A1 (en) | 2009-12-18 | 2011-06-23 | Novartis Ag | 4-aryl-butane-1,3-diamides |
| WO2011076744A1 (en) | 2009-12-21 | 2011-06-30 | Novartis Ag | Disubstituted heteroaryl-fused pyridines |
| WO2011076747A1 (en) | 2009-12-21 | 2011-06-30 | Novartis Ag | Diaza-spiro[5.5]undecanes as orexin receptor antagonists |
| WO2011138265A2 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indole and indazole derivatives as orexin receptor antagonists |
| WO2011138266A1 (en) | 2010-05-03 | 2011-11-10 | Evotec Ag | Indolizine and imidazopyridine derivatives as orexin receptor antagonists |
| MX2013006715A (es) | 2010-12-17 | 2013-08-26 | Taisho Pharmaceutical Co Ltd | Derivado de pirazol. |
| US20120165339A1 (en) | 2010-12-22 | 2012-06-28 | Eisai R&D Management Co., Ltd. | Cyclopropane derivatives |
| US20120165331A1 (en) | 2010-12-22 | 2012-06-28 | Sangamesh Badiger | Di/tri-aza-spiro-C9-C11alkanes |
| WO2012085857A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| CA2823877C (en) | 2011-02-18 | 2020-01-07 | Idorsia Pharmaceuticals Ltd | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2012145581A1 (en) | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| WO2012153729A1 (ja) | 2011-05-10 | 2012-11-15 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
| US20140228377A1 (en) | 2011-07-05 | 2014-08-14 | Taisho Pharmaceutical Co., Ltd. | Methylpiperidine derivative |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US9029364B2 (en) | 2011-10-21 | 2015-05-12 | Merck Sharp & Dohme Corp. | 2,5-disubstituted thiomorpholine orexin receptor antagonists |
| WO2013062857A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Piperidinyl alkyne orexin receptor antagonists |
| EP2771346A4 (en) | 2011-10-25 | 2015-06-03 | Merck Sharp & Dohme | ISOXAZOLOPYRIDIN-orexin |
| ES2572703T3 (es) | 2011-11-08 | 2016-06-01 | Actelion Pharmaceuticals Ltd. | Derivados de 2-(1,2,3-triazol-2-il)benzamida y 3-(1,2,3-triazol-2-il)picolinamida como antagonistas del receptor de orexina |
| ITMI20112329A1 (it) | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| CA2863413A1 (en) | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| BR112014019909B1 (pt) | 2012-02-17 | 2020-01-28 | Eisai R&D Man Co Ltd | processo para produção de compostos úteis como antagonistas do receptor de orexina-2 |
| ITMI20120322A1 (it) * | 2012-03-01 | 2013-09-02 | Rottapharm Spa | Composti di 4,4-difluoro piperidina |
| ITMI20120424A1 (it) | 2012-03-19 | 2013-09-20 | Rottapharm Spa | Composti chimici |
| TW201613891A (en) | 2014-02-12 | 2016-04-16 | Eolas Therapeutics Inc | Substituted prolines / piperidines as orexin receptor antagonists |
-
2015
- 2015-08-13 UY UY0001036272A patent/UY36272A/es not_active Application Discontinuation
- 2015-08-13 WO PCT/US2015/044974 patent/WO2016025669A1/en not_active Ceased
- 2015-08-13 ES ES15832417T patent/ES2901418T3/es active Active
- 2015-08-13 JP JP2017506968A patent/JP6663909B2/ja active Active
- 2015-08-13 AR ARP150102622A patent/AR101558A1/es unknown
- 2015-08-13 TW TW104126419A patent/TW201613902A/zh unknown
- 2015-08-13 US US15/503,131 patent/US10221170B2/en active Active
- 2015-08-13 EP EP15832417.8A patent/EP3180332B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6663909B2 (ja) | 2020-03-13 |
| ES2901418T3 (es) | 2022-03-22 |
| US10221170B2 (en) | 2019-03-05 |
| WO2016025669A1 (en) | 2016-02-18 |
| JP2017524005A (ja) | 2017-08-24 |
| AR101558A1 (es) | 2016-12-28 |
| UY36272A (es) | 2016-02-29 |
| EP3180332A4 (en) | 2018-01-24 |
| US20170226103A1 (en) | 2017-08-10 |
| EP3180332A1 (en) | 2017-06-21 |
| EP3180332B1 (en) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201613902A (en) | Difluoropyrrolidines as orexin receptor modulators | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| CL2015002123A1 (es) | Moduladores de receptores nmda de espiro-lactama y sus usos | |
| PH12016501966B1 (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| SG10201806867VA (en) | Dll3 modulators and methods of use | |
| NZ724878A (en) | Compounds and compositions as toll-like receptor 7 agonists | |
| MX2015016171A (es) | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. | |
| BR112016001974A2 (pt) | processo para a preparação de uma partícula, partícula obtidaa partir do processo, composição líquida, composição para cuidado doméstico ou cuidados pessoais e método de tratamento de um substrato | |
| PH12015502293A1 (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| MX384192B (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| PH12014502095A1 (en) | Estrogen receptor modulators and uses thereof | |
| PH12018501708A1 (en) | Halo-substituted piperidines as orexin receptor modulators | |
| MX2015011132A (es) | Moduladores policiclicos del receptor de estrogenos y sus usos. | |
| JOP20190175A1 (ar) | مركبات تعمل كمعدِّل لمستقبل هيدروكربون الأريل (AhR) | |
| EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
| NZ730334A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
| MY177915A (en) | Il-21 antibodies | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| MX2017005484A (es) | Compuestos antagonistas del receptor de dopamina d3. | |
| MX2017011344A (es) | Anticuerpos diseñados de sitio específico y métodos de uso. | |
| MX2022000242A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
| UA117779C2 (uk) | Піразини як модулятори gpr6 |